1.20
-0.04 (-3.23%)
-0.04 (-3.23%)
Upgrade to Real-Time
Regular Market
| Volume | 217,392 |
|
|||||
| News | - | ||||||
| Day High | 1.25 | Low High |
|||||
| Day Low | 1.20 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaxart Inc | VXRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -3.23% | 1.20 | 09:54:18 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.24 | 1.20 | 1.25 | 1.24 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 928 | 217,392 | $ 1.23 | $ 266,568 | - | 1.17 - 8.13 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:54:18 | 184 | $ 1.20 | USD |
Period:
Draw Mode:
Vaxart Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 157.50M | 131.25M | 117.29M | $ 892.00k | $ - | -0.58 | -1.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 428.55k | 2.50% |
Vaxart News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VXRT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.34 | 1.38 | 1.17 | 1.26 | 1,922,033 | -0.14 | -10.45% |
| 1 Month | 1.61 | 1.725 | 1.17 | 1.45 | 3,110,742 | -0.41 | -25.47% |
| 3 Months | 2.72 | 2.9359 | 1.17 | 1.87 | 3,028,895 | -1.52 | -55.88% |
| 6 Months | 3.72 | 4.615 | 1.17 | 2.76 | 2,810,540 | -2.52 | -67.74% |
| 1 Year | 7.70 | 8.13 | 1.17 | 3.94 | 2,839,297 | -6.50 | -84.42% |
| 3 Years | 0.3545 | 24.90 | 0.2805 | 7.42 | 9,999,988 | 0.8455 | 238.5% |
| 5 Years | 7.469 | 24.90 | 0.2543 | 7.31 | 6,247,278 | -6.27 | -83.93% |
Vaxart Description
| Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |